Evidence map›Paper›PMID 20167183›Full record

ReviewJournal of diabetes science and technology2010

Stomach dysfunction in diabetes mellitus: emerging technology and pharmacology.

Lawrence A Szarka, Michael Camilleri

Open access · bronzeAbstract readReview
In one paragraph

Review in Journal of diabetes science and technology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Lawrence A SzarkaClinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), College of Medicine, Mayo Clinic, Rochester, Minnesota.
Michael Camilleri
Mayo Clinic · US

Funding

Pharmacogenomics of Gastric Function &Weight in ObesityR01DK067071 · NIDDK · MAYO CLINIC ROCHESTER · PI CAMILLERI, MICHAEL L. · 2004 to 2020
$4.7M
NIDDK NIH HHS R01 DK 67071
6 · The paper itself

Abstract

Gastroparesis and other types of gastric dysfunction result in substantial morbidity in diabetes patients. The pathophysiology of these disorders is incompletely understood. This article reviews techniques applicable to the assessment of gastric function in diabetes patients, including the measurement of emptying, accommodation, and contractility. Available treatment options are also reviewed, including novel yet unapproved serotonin 5-HT(4) agonist pharmacological treatments, as well as the role of endoscopic, surgical, and device treatments of gastroparesis.

Indexed as

Bariatric SurgeryDiabetes ComplicationsDiabetic NeuropathiesDiagnostic Techniques, Digestive SystemDrug TherapyElectric StimulationGastrointestinal MotilityGastroparesisHumansPharmacologyStomach Diseases

Identifiers

PMID20167183
PMCPMC2825640
OpenAlexW1974878496

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.